TLX News: First Patient Dosed in Phase II Renal Cancer Theranostics Study - 5th May 2022, 7:00am

[annb0t]

MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177Lu-DOTA-girentuximab), at Memorial Sloan Kettering Cancer Center (MSK) in New York. (PRNewsfoto/Telix Pharmaceuticals Limited)

STARLITE 2 (NCT05239533) will assess the efficacy of TLX250 targeted radiation in combinati...

>>> Read more: First Patient Dosed in Phase II Renal Cancer Theranostics Study